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Steven E. Lipshultz1*, Giorgio Minotti2, Joseph Carver3 and Vivian I. Franco1Advances in cancer treatments have brought hope to
patients with these diseases once thought to be incur-
able. However, these same treatments can inadvert-
ently harm healthy cells and affect systems unrelated
to the cancer, especially the cardiovascular system [1].
A precise definition of cardiotoxicity is still lacking
[2]. However, an overwhelming body of evidence has
established that patients exposed to antitumor therap-
ies have several laboratory or clinical indices of
cardiovascular dysfunction and that become more evi-
dent as patients live longer. As a result, patients with
cancer who have or who are at risk of cardiovascular
toxicity are now being treated collaboratively by
oncologists-hematologists, radiotherapists, and cardiol-
ogists, which has led to a new interdisciplinary field,
cardio-oncology.
The journal Cardio-Oncology is a dedicated forum for
oncologists, cardiologists, researchers, and other health
providers who care for patients who have survived or
who are being treated for cancer. It also provides the op-
portunity for the latest and highest quality evidence in
this emerging field to be widely shared in the medical
community. The mission of Cardio-Oncology is to pub-
lish research that addresses the balance between curing
cancer and limiting the adverse cardiovascular effects of
cancer treatment. To achieve this mission, we welcome
a broad range of original research and review articles ad-
dressing many questions in this complex field from a
multidisciplinary approach. Cardio-oncology has many
areas of research. Here, we highlight some of the more
pressing issues in the field and invite authors to submit
for publication their work on these and other issues.
First, we have to better understand the risks of cardio-
vascular toxicity to establish effective prevention and
surveillance protocols. A lack of awareness or underesti-
mating the cardiovascular risks of cancer treatment* Correspondence: slipshultz@med.wayne.edu
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the long term. Many risk factors for cardiovascular tox-
icity have been identified in cancer patients during and
after treatment. These factors include a cumulative dose
of anthracycline (≥400 mg/m2 for adults [≥18 years old]
and ≥300 mg/m2 for children [<18 years old]) [3], con-
comitant radiation therapy, younger or older age at diag-
nosis, female sex, black race, and the presence of other
cardiovascular comorbidities.
However, the differences between patients who do and
do not develop cardiotoxicity are substantial, even if they
have some of the same risk factors. To explain these dif-
ferences, investigators have explored possible genetic in-
volvement. For example, hereditary hemochromatosis is
a genetic disorder of iron metabolism that leads to iron
overload-associated tissue injury. In this disorder, gene
mutations in the C282Y allele are associated with myo-
cardial injury in anthracycline-treated survivors of child-
hood acute lymphoblastic leukemia [4]. This mutation
might cause excess iron accumulation in cardiac cells
and increase the heart’s vulnerability to damage from the
free radicals formed by the doxorubicin-iron complexes,
but the actual mechanisms are not known. Another
study found an increased risk of cardiomyopathy in
patients exposed to low-to-moderate doses of anthracy-
clines. These patients were homozygous for the G allele
in the carbonyl reductase 3 gene and presumably formed
higher levels of a toxic anthracycline metabolite [5, 6].
Although additional studies are needed to validate these
genetic risk factors, behavioral risks, such as smoking,
physical inactivity, excess body weight, and alcohol con-
sumption, also deserve further exploration and are be-
coming increasingly important as survivors increase in
number and in age.
It is also necessary to understand the pathophysiology
and mechanisms of cardiotoxicity of both old and new
treatment regimens. Multiple mechanisms of cardiotoxi-
city have been proposed for anthracyclines, but less is
known about other chemotherapeutics or the new gen-
eration of “targeted” drugs. Lessons from trastuzumable is distributed under the terms of the Creative Commons Attribution 4.0
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otoxicity but instead cause myocardial dysfunction and
reduce cardiac defenses and repair mechanisms against
anthracyclines or pathophysiologic stressors (e.g., hyper-
tension) [7]. Other new drugs (antibodies, kinase inhibi-
tors) may induce vasoconstriction, hypertension, or
thrombosis by disrupting the nitric oxide pathway or
other vasodilator mechanisms [7]. That said, cardiovas-
cular toxicity from these newer agents seems to differ
greatly from that of the anthracyclines. This difference is
the basis for the simple but not all-inclusive classifica-
tion of anthracyclines and “targeted” agents as type 1
and type 2 agents, respectively [8]. Clearly, much
remains to be understood about these agents and their
effects. This calls for preclinical models that identify risk
and mechanisms of cardiotoxicity with a high level of
predictability but unfortunately many cellular and ani-
mal models are limited by inherent pitfalls and do not
always help decipher the cardiovascular toxic potential
of one agent or another [9]. Newer approaches are much
needed. Having clinicians and basic researchers work
together may offer unprecedented opportunities to
exchange information and provide mechanism-based
information that translates into clinical facts.
Compared to the vast number of studies on cardiovas-
cular toxicity and cancer in adults, the number of similar
studies in children is almost sparse. Hence, many
pediatric treatment protocols are extrapolated from
those for adults, which is not always appropriate, given
the differences in body composition and developmental
changes in children. An example is the use of continu-
ous anthracycline infusion, which reduces cardiotoxicity
in adults. Limited evidence in children with high-risk
acute lymphoblastic leukemia, however, indicates that
continuous infusion is not more cardioprotective than
bolus infusion of anthracyclines [10]. Hence, the lack of
benefit is outweighed by the added expense of longer
hospital stays and the increased risk of complications,
suggesting that continuous infusion of anthracyclines be
discontinued in children until there is more evidence to
the contrary. Similarly, liposomal anthracyclines, given
their unique pharmacokinetics, reduce the risk of cardio-
toxicity in adults with solid tumors [11], but evidence of
their effect in children is scarce and preliminary at best
[12]. Also lacking are long-term follow-up studies to
determine whether their use increases the risk of late
cardiac effects.
In a similar manner, relatively few clinical studies in-
clude older cancer patients. In everyday clinical practice
the elderly are often undertreated because of concerns
about cardiovascular complications. This may lead to
treatment modalities that lack curative effects, particu-
larly when anthracyclines are administered in lower
doses or fewer cycles or are replaced by less active drugs.Yet, there is evidence that full-dose anthracyclines could
be safely administered to the elderly at risk for cardio-
toxicity, provided that clinicians were expert enough to
split the cumulative dose of anthracyclines in more
numerous cycles as compared to standard protocols
adopted in young-adult patients [13]. Again, this calls
for newer forms of collaborations between oncologists,
cardiologists and geriatricians, and for newer preclinical
models in which cardiovascular liability of antitumor
drugs in the elderly could be explored with a satisfactory
level of predictability.
Addressing these issues may help inform treatment
planning, which includes prevention and surveillance
strategies. Altering cancer treatment to reduce or pre-
vent toxic effects would be unethical without supporting
evidence from well-designed studies. It is also important
to ensure that preventive strategies do not interfere with
oncologic efficacy or increase the risk of recurrence or
secondary malignancy. Dexrazoxane, a multifunctional
drug than can both chelate iron and inhibit topoisome-
rases, has important cardioprotective effects [14, 15] and
is currently only approved by the FDA for use in adults
with metastatic breast cancer who have received a cu-
mulative dose of 300 mg/m2 of doxorubicin and who
may benefit from continued treatment with an anthracy-
cline [16]. Studies in children with high-risk cancer have
also documented that dexrazoxane is cardioprotective
when administered before each dose of doxorubicin [15],
leading the FDA to designate dexrazoxane as a drug for
orphan diseases in August 2014. Increasing evidence
favors including dexrazoxane in anthracycline-based
treatment protocols [17]. However, the cardioprotection
afforded by dexrazoxane has been limited to patients
receiving anthracyclines.
Another important factor related to cardioprotection
is the timing of administering or implementing these
treatments. For example, in adults, dexrazoxane admin-
istration is recommended only after a patient has already
received 300 mg/m2 of doxorubicin to protect the heart
from any subsequent exposure to anthracycline. In con-
trast, to prevent irreversible cardiac damage to the de-
veloping heart, dexrazoxane is more effective in children
if given as first-line therapy before each dose of doxo-
rubicin. In this case, the reason for this difference in
timing is understandable – children are more vulnerable
to cardiac damage than adults because their hearts are
still developing. However, the reasons for other differ-
ences are not so clear. Enalapril is often given after can-
cer therapy to treat cardiac damage that manifest later
in follow up, but some studies suggest that cardiovascu-
lar drugs could be given during treatment to protect the
heart [18]. It has also been shown that the earlier that
heart failure treatment is started after biomarker evi-
dence of cardiac damage/dysfunction, the less likely is
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childhood cancer survivors with asymptomatic and symp-
tomatic cardiac dysfunction treated with enalapril after
completing chemotherapy, left ventricular structure and
function improved temporarily, but after 6 to 10 years of
enalapril treatment, these improvements were lost, and in
some cases were even reversed [20].
On the other hand, in a randomized trial of adults
with hematologic malignancies, patients received either
combination cardiac therapy with enalapril and carve-
dilol (intervention) or no additional treatment (controls)
during chemotherapy [18]. After 6 months, left ventricu-
lar ejection fraction was significantly reduced in the con-
trol group but was unchanged in the intervention group.
Although the results of this short-term follow-up are
promising, whether the benefits will be lost as it does in
childhood cancer survivors is unknown.
Surveillance of cardiotoxicity is most commonly done
using echocardiographic assessment of left ventricular
ejection fraction. However, echocardiography is limited
by preload and unavoidable operator-dependent biases.
Further, it may not always detect cardiac abnormalities
that precede decrements in ejection fraction and that re-
quire early treatment with cardiovascular drugs. Other
promising methods include cardiac MRI, which can be
cost-prohibitive, and strain and strain rate echocardiog-
raphy, which require additional studies to validate their
results.
Serum cardiac biomarkers are commonly used to
assess cardiac status in patients without cancer, and
they may detect early cardiac damage in children. In
survivors of childhood high-risk acute lymphoblastic
leukemia, elevated concentrations of cardiac troponin
T (cTnT) and N-terminal probrain natriuretic peptide
(NT-proBNP) during the first 90 days of treatment were
associated with abnormal echocardiographic findings
4 years later, suggesting that these biomarkers might help
predict early cardiac damage [21]. In adults, elevated
concentrations of troponin [22] and NT-proBNP [23] pre-
ceded decrements in left ventricular ejection fraction.
However, additional studies are needed before these
markers can inform treatment decisions in daily practice.
Future directions
It is becoming clear that individual risks alone do not pre-
dict cardiotoxicity, which suggests that specific risk groups
might be identified and studied for the cardiovascular ef-
fects of tailored treatment protocols. Understanding the
mechanisms of treatment-related cardiotoxicity might
help identify potential areas of drug development. It is also
important to continue exploring a variety of cardioprotec-
tive strategies in studies carefully designed to reliably
measure and compare their efficacy and safety. Lastly, it
may be possible to establish evidence-based guidelines toinform treatment decisions unique to each patient to
ensure the proper balance of care.
We have mentioned only a few unsettled issues in
cardio-oncology. Many other questions await answers and
clinical directions, and many more will emerge as oncolo-
gists, hematologists, radiation therapists, and pharmacolo-
gists test new drugs and treatment protocols. We trust
that this new journal, Cardio-Oncology, will become a
valuable forum for presenting preclinical and clinical
research on this complex field of medicine. The Editors
welcome suggestions and encourage all cardio-oncologists
to submit their work to Cardio-Oncology. As is the case
for all journals, the success of Cardio-Oncology depends
on the enthusiasm, the scientific curiosity, and the support
the scientific and clinical community and their authors.
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